Case Study | April 09, 2015

The CyberKnife System Provides an Alternative for Lung Cancer Patients

Erlanger Health System uses the cyberknife system to provide fiducial-free treatment for early-stage lung cancer patients

A 3-D, axial, sagittal and coronal view of the treated areahighlighted in pink, as well as radiation dose shown in multicoloredisodose lines.

2-View: A 3-D, axial, sagittal and coronal view of the treated areahighlighted in pink, as well as radiation dose shown in multicoloredisodose lines.

Orthogonal planar images showing the position of the tumor during initial simulation to determine the method in which the tumor is tracked during treatment. Notice that the tumor is only clearly visible in Image A.

1-View: Orthogonal planar images showing the position of the tumor during initial simulation to determine the method in which the tumor is tracked during treatment. Notice that the tumor is only clearly visible in Image A.

A 3-D, axial, sagittal and coronal view of the treated areahighlighted in pink, as well as radiation dose shown in multicoloredisodose lines.

2-View: A 3-D, axial, sagittal and coronal view of the treated areahighlighted in pink, as well as radiation dose shown in multicoloredisodose lines.

Erlanger Health System in Chattanooga, Tennessee, purchased a CyberKnife Robotic Radiosurgery System in December 2010 to develop a stereotactic body radiation therapy (SBRT) program in its Radiation Oncology Department. The CyberKnife System included the Lung Optimized Treatment (LOT) function, which provides fiducial-free SBRT of early-stage lung cancer patients by enabling a hybrid method of spine tracking and tumor density tracking. Once the CyberKnife System was in use, the clinical team at Erlanger collaborated with referring physicians to explain to thoracic surgeons and pulmonologists — at Erlanger and other hospitals in the community — how the system could be utilized as a treatment option for their patients.

Lung Optimized Treatments: 2-View

The CyberKnife LOT function offers several solutions for patients with lung tumors, including the 2-View tracking solution, which uses both of the system’s ceiling-mounted X-ray cameras, along with Synchrony Respiratory Tracking to automatically track and adjust the beam to tumor motion. This function was used to treat a 70-year-old woman whose cancer had returned after previous therapy. She received treatment three-and-a-half years prior with conventional radiation therapy to 6480cGy over the course of 36 fractions. In addition, four cycles of Taxotere and Carboplatin had been administered neoadjuvantly. However, PET/CT showed a 1.8cm hypermetabolic nodule in the right medial lung base.

The Surgical solutions and conventional radiation therapy were not options for this recurrence, so physicians agreed that SBRT was an excellent opportunity to eradicate or provide long-term suppression to the area of recurrence. Based on the 2-View LOT protocol, a prescription dose of 6000cGy was prescribed to the 82 percent isodose line and delivered over three fractions utilizing 111 non-coplanar beams.

Eight months after treatment, a CT scan showed no residual tumor in the medial right lobe.

Lung Optimized Treatments: 1-View

Another treatment protocol available with Erlanger’s CyberKnife System is the 1-View LOT function. The 1-View LOT protocol uses one of the CyberKnife’s two orthogonally mounted X-ray cameras to enable fiducial-free, real-time adjustment of the beam to the respiratory motion of the tumor. A margin is then added to the tumor volume to account for the motion that would have been seen only in the “blind“ X-ray camera view. This protocol was utilized for a 70-year-old woman with medically inoperable, stage I, poorly differentiated large cell carcinoma of the right/mid upper lobe at the hilum. She was not a surgical candidate due to poor pulmonary function, and physicians did not believe that she would tolerate conventional radiation therapy. However, foregoing therapy had an associated risk of progression and lymphatic spread, which could occur within a matter of months.

Physicians chose to treat the patient with non-invasive SBRT. While side effects, including coughing and chest wall or rib tenderness are possible, the probability for this patient was low due to the location of the tumor.

Based on the 1-View LOT function, the treatment plan was developed using the MultiPlan® Treatment Planning System, and a dose of 5400cGy was prescribed to the 82 percent isodose line and delivered over four fractions, utilizing 98 non-coplanar beams. Each fraction lasted approximately 36 minutes.

Aside from reports of fatigue one week after completion of treatments, the patient had no complaints. Seven months post-treatment, the patient reported doing well. She was not on oxygen and indicated she had no shortness of breath. The treated lesion was no longer visible in CT scans taken at three- and six-month follow-ups.

Lung Optimized Treatments: 0-View

The third LOT function that Erlanger uses with its CyberKnife System is the 0-View option. The 0-View LOT protocol is used when a tumor cannot be clearly identified by either of the CyberKnife’s two X-ray cameras. The planning margin is expanded to include the entire inhale-to-exhale tumor motion. Erlanger used this feature with a 72-year-old man with a stage I lung cancer in the left upper and mediastinal nodal sampling, as well as wedge resection. But the patient was considered a marginal operative risk and he wanted to explore less invasive interventions.

Physicians suggested SBRT as a non-invasive alternative to surgery. SBRT using the CyberKnife System is equivalent to surgical wedge resection with respect to local control. Additionally, the LOT treatment would not require placement of any fiducials and was unlikely to cause adverse side effects given the location of his lesion.

Based on the 0-View LOT protocol, the clinical team utilized both inhale and exhale CT data sets to design a treatment plan on the MultiPlan® Treatment Planning system. The tumor excursion was measured and PTV margins drawn to account for the extent of tumor motion.

The patient was treated using the CyberKnife System’s automated IrisTM Variable Aperture Collimator. A prescription dose of 6000cGy was prescribed to the 81 percent isodose line and delivered over three fractions, lasting approximately 24 minutes each, utilizing 77 non-coplanar beams. Aside from reports of fatigue about a week after his final treatment, the patient had no complaints. One year after treatment, at his follow-up visit, the patient was still doing well with no distress.

Benefits of CyberKnife for Early Stage Lung Cancer

The CyberKnife System provides early-stage lung cancer patients at Erlanger with an alternative treatment option to surgery. “Often we get patients who wonder if there is a treatment for them,” said David Taliaferro, CyberKnife coordinator at Erlanger’s CyberKnife Center. “We find it very gratifying that now we can tell our patients that we indeed have a treatment option for them. Not only that, but it is quick, painless, and non-invasive.”

Related Content

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
SIIM and ACR Host Machine Learning Challenge for Pneumothorax Detection and Localization
News | Artificial Intelligence | June 03, 2019
The Society for Imaging Informatics in Medicine (SIIM) and the American College of Radiology (ACR) are collaborating...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis
Vast Majority of Heavy Smokers Not Screened for Lung Cancer
News | Lung Cancer | May 29, 2019
Out of more than 7 million current and former heavy smokers, only 1.9 percent were screened for lung cancer in 2016...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin